Revision of Antifungal Strategies Definitions for Invasive Fungal Infections in Hematological Malignancies

Launched by SORVEGLIANZA EPIDEMIOLOGICA INFEZIONI FUNGINE EMOPATIE MALIGNE · Jul 17, 2019

Keywords

ClinConnect Summary

Primary objective The primary objective of this study is to evaluate IFI according to clinicians' opinion vs the opinion of an independent board of experts. The independent panel, confirming or not the decision of local physician, will review all cases (blind central review). The primary output of this study is the evaluation of inter-raters agreement.

Secondary objectives:

Evaluation of IFI incidence Description of clinical and laboratory features Frequencies of different antifungal treatments Description of outcome Impact on the treatment of underlying hematological malignancy

Study de...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients with hematologic malignancies at any stage of the disease (acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia, high and low grade non Hodgkin lymphoma, chronic myeloprolipherative disorders, Hodgkin lymphoma);
• • Only inpatients will be eligible;
• • Patient that start IV antifungal treatment (irrespective of previous prophylaxis);
• • Informed consent signed.
• Exclusion Criteria:
• • Patients with previous or undergoing allogeneic or autologous transplant will be excluded from the study, due to different clinical profiles and risk factors;
• • Patients treated, after prophylaxis with oral antifungals
• • Patients treated in outpatient clinic or Day hospital